vs
中国东方航空（EML）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是中国东方航空的1.3倍（$69.8M vs $55.3M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 1.0%，领先383.0%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -22.4%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -0.6%）
中国东方航空是中国境内的头部航空公司，总部位于上海长宁区，与中国国际航空、中国南方航空并称为中国三大骨干航空公司，航线网络覆盖全球多个国家和地区，是中国民航市场的核心运营商之一。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
EML vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.3倍
$55.3M
营收增速更快
RIGL
高出43.6%
-22.4%
净利率更高
RIGL
高出383.0%
1.0%
两年增速更快
RIGL
近两年复合增速
-0.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.3M | $69.8M |
| 净利润 | $578.9K | $268.1M |
| 毛利率 | 22.3% | 91.5% |
| 营业利润率 | 3.1% | 33.2% |
| 净利率 | 1.0% | 384.0% |
| 营收同比 | -22.4% | 21.2% |
| 净利润同比 | 103.8% | 1769.2% |
| 每股收益（稀释后） | $0.10 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMLRIGL
| Q4 25 | — | $69.8M | ||
| Q3 25 | $55.3M | $69.5M | ||
| Q2 25 | $70.2M | $101.7M | ||
| Q1 25 | $63.3M | $53.3M | ||
| Q4 24 | $64.3M | $57.6M | ||
| Q3 24 | $71.3M | $55.3M | ||
| Q2 24 | $72.6M | $36.8M | ||
| Q1 24 | $64.6M | $29.5M |
净利润EMLRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $578.9K | $27.9M | ||
| Q2 25 | $3.4M | $59.6M | ||
| Q1 25 | $1.9M | $11.4M | ||
| Q4 24 | $1.3M | $14.3M | ||
| Q3 24 | $-15.3M | $12.4M | ||
| Q2 24 | $3.5M | $-1.0M | ||
| Q1 24 | $1.9M | $-8.2M |
毛利率EMLRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | 22.3% | 93.2% | ||
| Q2 25 | 23.3% | 95.6% | ||
| Q1 25 | 22.4% | 91.7% | ||
| Q4 24 | 23.6% | 89.9% | ||
| Q3 24 | 25.5% | 85.5% | ||
| Q2 24 | 25.4% | 92.4% | ||
| Q1 24 | 23.9% | 93.1% |
营业利润率EMLRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | 3.1% | 40.9% | ||
| Q2 25 | 4.5% | 60.1% | ||
| Q1 25 | 5.1% | 23.9% | ||
| Q4 24 | 6.1% | 28.9% | ||
| Q3 24 | 9.5% | 25.4% | ||
| Q2 24 | 8.3% | 1.2% | ||
| Q1 24 | 5.3% | -23.6% |
净利率EMLRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 1.0% | 40.2% | ||
| Q2 25 | 4.9% | 58.6% | ||
| Q1 25 | 3.1% | 21.5% | ||
| Q4 24 | 2.0% | 24.9% | ||
| Q3 24 | -21.5% | 22.5% | ||
| Q2 24 | 4.8% | -2.8% | ||
| Q1 24 | 3.0% | -27.9% |
每股收益（稀释后）EMLRIGL
| Q4 25 | — | $14.11 | ||
| Q3 25 | $0.10 | $1.46 | ||
| Q2 25 | $0.56 | $3.28 | ||
| Q1 25 | $0.32 | $0.63 | ||
| Q4 24 | $0.22 | $0.82 | ||
| Q3 24 | $-2.46 | $0.70 | ||
| Q2 24 | $0.56 | $-0.06 | ||
| Q1 24 | $0.31 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.2M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $124.3M | $391.5M |
| 总资产 | $220.0M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EMLRIGL
| Q4 25 | — | $155.0M | ||
| Q3 25 | $9.2M | $137.1M | ||
| Q2 25 | $9.1M | $108.4M | ||
| Q1 25 | $10.2M | $77.1M | ||
| Q4 24 | $16.1M | $77.3M | ||
| Q3 24 | $9.7M | $61.1M | ||
| Q2 24 | $2.0M | $49.1M | ||
| Q1 24 | $2.1M | $49.5M |
总债务EMLRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | $42.2M | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益EMLRIGL
| Q4 25 | — | $391.5M | ||
| Q3 25 | $124.3M | $117.6M | ||
| Q2 25 | $124.4M | $81.9M | ||
| Q1 25 | $121.0M | $18.6M | ||
| Q4 24 | $120.7M | $3.3M | ||
| Q3 24 | $119.2M | $-14.6M | ||
| Q2 24 | $136.5M | $-29.9M | ||
| Q1 24 | $134.5M | $-31.7M |
总资产EMLRIGL
| Q4 25 | — | $513.6M | ||
| Q3 25 | $220.0M | $242.5M | ||
| Q2 25 | $229.4M | $206.7M | ||
| Q1 25 | $232.3M | $176.0M | ||
| Q4 24 | $235.3M | $164.0M | ||
| Q3 24 | $244.2M | $139.4M | ||
| Q2 24 | $255.9M | $128.4M | ||
| Q1 24 | $253.9M | $126.5M |
负债/权益比EMLRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | 0.35× | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $3.1M | — |
| 自由现金流率自由现金流/营收 | 5.5% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 5.38× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $12.3M | — |
8季度趋势，按日历期对齐
经营现金流EMLRIGL
| Q4 25 | — | $22.0M | ||
| Q3 25 | $3.1M | $24.0M | ||
| Q2 25 | $3.8M | $30.5M | ||
| Q1 25 | $-1.8M | $-893.0K | ||
| Q4 24 | $11.0M | $14.5M | ||
| Q3 24 | $-2.9M | $21.7M | ||
| Q2 24 | $8.4M | $302.0K | ||
| Q1 24 | $2.8M | $-5.0M |
自由现金流EMLRIGL
| Q4 25 | — | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-2.7M | — | ||
| Q4 24 | $9.0M | — | ||
| Q3 24 | $-7.7M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $1.1M | — |
自由现金流率EMLRIGL
| Q4 25 | — | — | ||
| Q3 25 | 5.5% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | -4.3% | — | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | -10.8% | — | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | 1.7% | — |
资本支出强度EMLRIGL
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 2.6% | — |
现金转化率EMLRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 5.38× | 0.86× | ||
| Q2 25 | 1.09× | 0.51× | ||
| Q1 25 | -0.95× | -0.08× | ||
| Q4 24 | 8.41× | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | 2.40× | — | ||
| Q1 24 | 1.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
